Series B

Neuspera restimulates $26m series B
Neuspera Medical has secured a $12m extension to bring its series B round to the targeted $26m close, with all investors from the first tranche returning.
Complion complies for $7m series B
Complion collected funding from investors including the multi-university-backed Ohio Innovation Fund for its regulatory compliance software platform catered to sites conducting clinical research.
6Estates tends to series B round
6Estates had previously raised $2m of funding for its market intelligence products based on research from NUS and Tsinghua University.
KenSci foretells $22m series B
The UW-founded healthcare forecasting software developer has collected $30.5m in all from backers including OUP and a unit of compliance firm UL.
Spin Memory banks Abies for series B
NYU and Allied Minds-founded Ram technology developer Spin Memory has unveiled deep tech-focused VC firm Abies Ventures as an investor in a $52m series B first announced late last year.
Bolt hits series B with $54m
Nan Fung Life Sciences and Novo have taken part in a series B round for Stanford's immuno-oncology drug developer Bolt Biotherapeutics.
Knotch captures $20m series B
Backed by Stanford-StartX Fund, marketing intelligence platform Knotch has now secured at least $31.5m in total funding and will now pursue technology upgrades and and internal expansion.
Nexiot checks in series B funding
ETH Zurich-founded smart logistics spinout Nexiot has won backing from Credit Suisse and Die Mobiliar Versicherungen as it aims to secure additional international business for its products.

Other News

CIC makes cut in Imagen series B
University of Cambridge’s affiliate patient capital fund has returned to take part in an $8.4m round for video content management platform Imagen after previously investing in 2014 and 2016.
Exscientia sends for $26m
Celgene and Evotec have put capital into Exscientia as the Dundee-founded automated drug discovery services provider added Roche to its roster of development partners.
Cabaletta Bio captures $50m
Autoimmune disease therapy spinout Cabaletta Bio's series B round brought its total to at least $88m allowed the university to pare back its shareholding.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Boosted hitches $60m series B ride
Stanford-StartX Fund has returned to pump funding into electric skateboard manufacturer Boosted, helping to take the company’s total funding to $70m.
Morphogen-IX clears path to series B round
Pulmonary arterial hypertension therapy business Morphogen-IX has been backed by Cambridge Enterprise and Cambridge Innovation Capital in a $23.3m round.

Editor's Picks

Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Canvas paints $9m picture
Canvas Network, an online education platform developed by learning management software (LMS) provider Instructure which received $9.1m investment for the platform, has begun offering free and open online courses.
WRF finds its Resolve
In May 2010, Resolve raised $2m in the initial close of its A round before bringing in a corporate venturing unit later.
Imperial helps PsiOxus raise $34m
UK-listed investment fund Imperial Innovations joins GlaxoSmithKline's SR One, fund manager Invesco Perpetual and Lundbeckfond Ventures, backing the d cancer treatment company.
test reg

Login